Mega Genomics (HKSE:06667) ROCE %: 0.16% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06667 Mega Genomics Ltd HKSE:06667
71 GF Score
Price HK$7.08
GF Value HK$16.92
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Mega Genomics ROCE %?

Mega Genomics HKSE:06667 -0.28% 71 ROCE % is 0.16% as of Dec. 2025. GuruFocus rates HKSE:06667 with a GF Score™ of 71/100 and a GF Value™ of HK$16.92 (Possible Value Trap). The stock has 8 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Mega Genomics's annualized ROCE % for the quarter that ended in Dec. 2025 was 0.16%.

Mega Genomics  (HKSE:06667) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Mega Genomics ROCE % Related Terms

Mega Genomics ROCE % Historical Data

* Premium members only.

The historical data trend for Mega Genomics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mega Genomics ROCE % Chart

Mega Genomics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial 23.16 -2.97 5.63 8.19 5.43

Mega Genomics Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.58 3.36 10.50 0.16 10.26
HKSE:06667
71GF Score
Mega Genomics Ltd HKSE:06667
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mega Genomics ROCE % Calculation

Mega Genomics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=37.774/( ( (788.451 - 96.774) + (919.569 - 220.984) )/ 2 )
=37.774/( (691.677+698.585)/ 2 )
=37.774/695.131
=5.43 %

Mega Genomics's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=1.156/( ( (752.046 - 41.701) + (919.569 - 220.984) )/ 2 )
=1.156/( ( 710.345 + 698.585 )/ 2 )
=1.156/704.465
=0.16 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.16% mean?
Mega Genomics (HKSE:06667) has a ROCE % of 0.16% as of Dec. 2025.
Is Mega Genomics' ROCE % too high?
Mega Genomics' current ROCE % is 0.16%. The Medical Diagnostics & Research industry median ROCE % is 0.50. Mega Genomics' value of 0.16% is 68% below this industry median. Overall, Mega Genomics has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mega Genomics' ROCE % compare to TMO and DHR?
Mega Genomics' ROCE % of 0.16% can be compared against companies in the Medical Diagnostics & Research industry. The industry median ROCE % is 0.50. Mega Genomics' value of 0.16% is 68% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
The median ROCE % among Medical Diagnostics & Research companies is 0.50, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mega Genomics's current ROCE % of 0.16% is 68% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median ROCE % is 0.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mega Genomics's current ROCE % is 0.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mega Genomics stock overvalued right now?
Based on GuruFocus' analysis, Mega Genomics (HKSE:06667) is currently considered Possible Value Trap. The stock's GF Value™ is HK$16.92, compared to a current price of HK$7.08 — trading 58.2% below its estimated fair value. The current ROCE % is 0.16% and 68% below the Medical Diagnostics & Research industry median of 0.50. Mega Genomics' overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Mega Genomics (HKSE:06667), the current ROCE % is 0.16% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mega Genomics (HKSE:06667) Overvalued in 2026?

Based on GuruFocus' analysis, Mega Genomics stock appears to be undervalued. The current stock price of HK$7.08 is trading 58.2% below its estimated GF Value™ of HK$16.92. GuruFocus considers Mega Genomics to be Possible Value Trap.

Key valuation signals for HKSE:06667:

  • ROCE %: 0.16%
  • GF Value™: HK$16.92 vs. price of HK$7.08 (58.2% below fair value)
  • GF Score™: 71/100 with 8 warning signs
  • Industry Position: 68% below the Medical Diagnostics & Research median

No single metric tells the full story. See the HKSE:06667 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mega Genomics Business Description

Address North Garden Road, 401 Health Work, Haidian District, Beijing, CHN
Mega Genomics Ltd is a genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services, ancillary services, and related products in the PRC. The company has launched dozens of testing services, covering a wide range of fields such as nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, cancer screening, and infectious disease diagnosis, to meet consumers' growing preventive medical needs. It generates a majority of its revenue from consumer genetic testing services.
71GF Score

Get the complete analysis for HKSE:06667

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$7.08
Price
HK$16.92
GF Value